Characterizing hospitalizations of end-stage renal disease patients on dialysis and inpatient utilization of erythropoiesis-stimulating agent therapy

Annals of Pharmacotherapy

Volumn 44, Issue 1, 2010, Pages 43-49

  Brophy, Donald F ^a   Daniel, Gregory ^b   Gitlin, Matthew ^c   Mayne, Tracy J ^c  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b HEALTHCORE INC   (United States)

^c AMGEN INC   (United States)

Author keywords

Dialysis; End stage renal disease; Erythropoiesis stimulating agents; Hospitalizations

Indexed keywords

ANTIANEMIC AGENT;

ADULT; AGED; ANEMIA; ARTICLE; COMORBIDITY; DRUG UTILIZATION; FEMALE; HEMODIALYSIS PATIENT; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGED; ANEMIA; CROSS-SECTIONAL STUDIES; ERYTHROPOIESIS; FEMALE; HEMATINICS; HOSPITALIZATION; HUMANS; INPATIENTS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; RETROSPECTIVE STUDIES;

EID: 74549213665     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M429     Document Type: Article

References (19)

1. US Renal Data System. USRDS 2008 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2008.
2. Possidente CD, Bailie GR, Hood VL. Disruptions in drug therapy in long-term dialysis patients who require hospitalization. Am J Health Syst Pharm 1999;56:1961- 4.
3. Hirth R, Greer S, Albert J, Young E, Piette J. Out-of-pocket spending and medication adherence among dialysis patients in twelve countries: out-of-pocket spending for drugs was related to national policies for drug financing, but the relationships were not always consistent. Health Aff 2008;27:89-102. DOI 10.1377/hlthaff.27.1.89
4. Ong SW, Fernandes OA, Cesta A, Bajcar JM. Drug-related problems on hospital admission: relationship to medication information transfer. Ann Pharmacother 2006;40:408-13. Epub 21 Feb 2006. DOI 10.1345/aph.1G482
5. Siegel J, Jorgenson J, Johnson P, et al. Use and prescribing patterns for erythropoiesis-stimulating agents in inpatient and outpatient hospital settings. Am J Health Syst Pharm 2008;65:1711-9.
6. Solid CA, Foley RN, Gilbertson DT, Collins A. Reaching target hemoglobin after hospitalization for incident hemodialysis patients (abstract). Hemodial Int 2004;8:92. DOI 10.1111/j.1492-7535.2004.0085ak.x
7. Solid CA, Foley RN, Gilbertson DT, Collins AJ. Perihospitalization hemoglobin-epoetin associations in US hemodialysis patients, 1998 to 2003. Hemodial Int 2007;11:442-7. DOI 10.1111/j.1542-4758.2007.00215.x
8. Ebben JP, Gilbertson DT, Foley RN, et al. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol 2006;1:1205-10. DOI 10.2215/CJN.01110306
9. Yaqub MS, Leiser J, Molitoris BA. Erythropoietin requirements increase following hospitalization in end-stage renal disease. Am J Nephrol 2001; 21:390-6. DOI 10.1159/000046281
10. Bradbury BD, Wang O, Critchlow CW, et al. Exploring relative mortality and epoetin alfa dose among hemodialysis patients. Am J Kidney Dis 2008;51:62-70. DOI 10.1053/j.ajkd.2007.09.015
11. Speigel D, Gitlin M, Mayne TJ. Factors affecting anemia management in hemodialysis patients - a single center experience. Hemodial Int 2008; 12:336-41. DOI 10.1111/j.1542-4758.2008.00278.x
12. Desai A, Bolus R, Nissenson A, et al. Identifying best practices in dialysis care: results of cognitive interviews and a national survey of dialysis providers. Clin J Am Soc Nephrol 2008;3:1066-76. DOI 10.2215/CJN.04421007
13. Healthcare Cost and Utilization Project (HCUP). Clinical Classification Software (CCS) Codes and User Guide 2009. Agency for Healthcare Research and Quality. www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp (accessed 2009 Mar 19).
14. Prescribing information. Epogen/Procrit (epoetin alfa). Thousand Oaks, CA: Amgen, November 2007.
15. Collins AJ, Li S, Peter W, et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit value of 36 to 39%. J Am Soc Nephrol 2001;12:2465-73.
16. Gitlin M, Hollenbeak CS, Mayne TJ. The potential impact on the US blood supply of blood transfusions in dialysis patients. Presented at: 2009 National Kidney Foundation Clinical Meeting, Dallas, Texas, April 2, 2009.
17. The Joint Commission. 2009 National Patient Safety Goals Hospital Program. www.jointcommission.org/NR/rdonlyres/31666E86-E7F4-423E-9BE8- F05BD1CB0AA8/0/HAP-NPSG.pdf (accessed 2009 Sep 14).
18. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006;47:S1-145.
19. Lacson E, Rogus J, Teng M, Lazarus JM, Hakim RM. The association of race with erythropoietin dose in patients on long-term hemodialysis. Am J Kidney Dis 2008;52:1104-14. DOI 10.1053/j.ajkd.2008.07.026